These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11595197)

  • 1. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention.
    Callahan A
    Am J Cardiol; 2001 Oct; 88(7B):33J-37J. PubMed ID: 11595197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
    Shukla A; Sharma MK; Jain A; Goel PK
    Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
    Gresser U; Gathof BS
    Eur J Med Res; 2004 Jan; 9(1):1-17. PubMed ID: 14766335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The statin dosage for achieving goal of cholesterol-lowering based on risk stratification in patients with ischemic cerebrovascular diseases].
    Tan ZF; Guo YD; Xu AD; Yang WY; Fu YG; Wang TG
    Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):280-3. PubMed ID: 19576114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
    Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ
    Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
    Goldstein LB; Amarenco P; Szarek M; Callahan A; Hennerici M; Sillesen H; Zivin JA; Welch KM;
    Neurology; 2008 Jun; 70(24 Pt 2):2364-70. PubMed ID: 18077795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
    Sever PS; Dahlöf B; Poulter NR; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2003 Apr; 361(9364):1149-58. PubMed ID: 12686036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the SPARCL trial and its subanalyses.
    Welch KM
    Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin therapy and stroke prevention.
    Vaughan CJ; Delanty N; Basson CT
    Curr Opin Cardiol; 2001 Jul; 16(4):219-24. PubMed ID: 11574782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPARCL: the glimmer of statins for stroke risk reduction.
    Armani A; Toth PP
    Curr Atheroscler Rep; 2007 Nov; 9(5):347-51. PubMed ID: 18001616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
    Semb AG; Holme I; Kvien TK; Pedersen TR
    Rheumatology (Oxford); 2011 Feb; 50(2):324-9. PubMed ID: 20884656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Thomason MJ; Mackness MI; Charlton-Menys V; Fuller JH;
    Lancet; 2004 Aug 21-27; 364(9435):685-96. PubMed ID: 15325833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.